Centene is poised for a turnaround driven by favorable Medicare Advantage payment changes and a strategic focus on membership quality. The author reiterates a ‘Buy’ rating, citing a compelling valuation with a 3-year PEG ratio of 0.35x and a potential price target of $91.60. Investors are advised to monitor technical indicators and consider potential pullbacks for a better entry point.
Summary
- Centene benefits from 2027 Medicare Advantage payment hikes and strategic membership attrition, driving a healthier membership base and improved Health Benefits Ratios.
- With further attrition expected through 2026, FY2026 may be a trough year, potentially explaining the management's mixed FY2026 guidance.
- Despite the recent rally, CNC remains compellingly valued with a 3Y PEG of 0.35x while offering a significant upside potential to a bull-case long-term price target of $91.60.
- Investors should monitor the overbought technicals and potential near-term pullbacks, potentially closer to the book value per share in the $43s for an improved margin of safety.
Gearstd/iStock via Getty Images
I previously rated Centene Corporation (CNC) as a Buy in February 2026, thanks to the management's excellent FY2026 guidance.
In this article, I shall discuss why I am reiterating my Buy rating here, with their premium repricing
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
